Kura Oncology Spins Off Caspian Therapeutics, Repurposing a Menin Inhibitor for Diabetes
- Kura Oncology spun off Caspian Therapeutics, a separately financed company pursuing menin inhibition for diabetes; Kura retains about 50% ownership, and CEO Troy Wilson chairs Caspian's board.
- Caspian launched with $50 million in financing led by BVF Partners, joined by Eli Lilly, T1D Fund, Invus, Montanova and Kura itself.
- Its lead candidate, KO-7246, targets the same menin-KMT2A interaction as Kura's FDA-approved leukemia drug ziftomenib, but is optimized for chronic metabolic disease rather than AML.
- Menin represses genes that limit pancreatic beta-cell growth; blocking it expanded beta-cell mass and boosted insulin production in preclinical type 1 and type 2 diabetes models.
- Caspian plans to file an IND and begin early trials assessing KO-7246's effects on beta-cell function and insulin output.
The spinout structure is the real story here: Kura offloads capital-intensive diabetes development onto a separately financed entity while keeping ~50% upside — a capital-efficient way to pursue a second indication without diluting the oncology balance sheet. Lilly's participation is the tell: not just funding, but a diabetes-franchise incumbent buying an option on a genuinely novel beta-cell-mass-expansion mechanism, distinct from GLP-1s and existing insulin-secretagogue classes. That novelty cuts both ways, though — menin inhibition is proliferative by design, and driving beta-cell expansion in pancreatic tissue carries an obvious tumorigenicity/hyperplasia overhang preclinical models won't fully resolve; watch how the IND-enabling tox package addresses it. Broader signal: oncology target biology migrating into metabolic disease is a repeatable playbook other biotechs with approved oncology assets may start mining.
Kura cancer drug discovery spurs launch of a diabetes biotech ↗